Oncology Institute (NASDAQ:TOI) Given “Buy” Rating at BTIG Research

BTIG Research reaffirmed a buy rating on Medline (NASDAQ:MDLN) with a $55.00 price objective, while also maintaining a buy rating on Oncology Institute (NASDAQ:TOI) with a $7.00 target. Zacks upgraded Medline to hold, Goldman Sachs set a buy rating and $49.00 target, and Sanford C. Bernstein began coverage.